Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical neurofibromas
Alexander Pemov, Douglas R. Stewart(Cancer Genetics (United States)), Javed Khan(Kent State University), Hilde Brems(Center for Human Genetics), Markku Miettinen(National Institutes of Health), Kristine Jones(Leidos (United States)), Jun S. Wei(Center for Cancer Research), Eva Dombi(National Institutes of Health), Nancy F. Hansen(National Institutes of Health), Eric Legius(Center for Human Genetics), Patricia Fetsch(National Institutes of Health), Rajesh Patidar, Brigitte C. Widemann(National Cancer Institute), James C. Mullikin(Human Genome Sciences (United States)), Margaret R. Wallace(University Medical Center), Settara C. Chandrasekharappa(National Human Genome Research Institute), Bin Zhu(National Institutes of Health), Christine S. Higham(University of California, San Francisco), Sivasish Sindiri(National Institutes of Health)
Cited by 118
Related Papers
A Draft Sequence of the Neandertal Genome
|Science|2010|4.6k
The complete sequence of a human genome
|Science|2022|3.3k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
A polymorphic DNA marker genetically linked to Huntington's disease
|Nature|1983|2.3k